Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
US-9556425-B2 · Jan 31, 2017 · US
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
US10189911B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10189911-B2 |
| Application number | US-201615365104-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 30, 2016 |
| Priority date | Apr 29, 2010 |
| Publication date | Jan 29, 2019 |
| Grant date | Jan 29, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
First claim
Opening claim text (preview).
We claim: 1. A therapeutic composition for detecting or modulating a biological activity of a splice variant polypeptide, comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) splice variant polypeptide that consists of SEQ ID NO: 14, 74, 76, or 78 or an epitope comprising at least 5 amino acids selected from SEQ ID NOs: 55, 57, 69, 182, 194, and 196, wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein. 2. The therapeutic composition of claim 1 , wherein the AARS polypeptide is selected from SEQ ID NO: 14, 74, 76, and 78. 3. The therapeutic composition of claim 1 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody. 4. The therapeutic composition of claim 1 , wherein the antibody is a humanized antibody. 5. The therapeutic composition of claim 1 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide. 6. The therapeutic composition of claim 1 , wherein the composition is a sterile, freeze-dried powder. 7. The therapeutic composition of claim 1 , wherein the composition is a sterile injectable solution. 8. The therapeutic composition of claim 1 , wherein the composition is buffered and comprises an isotonic agent. 9. The therapeutic composition of claim 1 , wherein the composition is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration. 10. The therapeutic composition of claim 1 , wherein the composition comprises a surfactant. 11. The therapeutic composition of claim 1 , wherein the composition has a purity of at least about 95% on a protein basis.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Antineoplastic agents · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10189911B2 cover?
- Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
- Who is the assignee on this patent?
- Atyr Pharma Inc, Pangu Biopharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).